Trial Profile
Open-Label, Randomized, Parallel Group, 3- or 4-Way Crossover Bioavailability Study of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 22 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Aug 2015 Planned End Date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record
- 06 Aug 2015 Planned primary completion date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record